M.D., Ph.D. (Genetics)
Over 20-year experience in cancer research and new drug development
Co-founder of four new drug R&D companies, including Ascenta (US) and Ascentage Pharma
Expert in general management, business development and fund rising
Former Managing Director of MorningSide Ventures
Assoc. Prof. of Georgetown Univ. and Michigan Univ. at Ann Arbor.
Author/co-author of 100+ papers and patents
Former President of Chinese Biopharmaceutical Association-USA (CBA); Member of BayHelix
“Special Contribution Award” from the CFDA
Editor in Chief: Journal of Medicinal Chemistry
Co-founder of Ascenta (US) and Ascentage Pharma
Warner-Lambert/Parke Davis Professor in Medicine, Univ. of Michigan at Ann Arbor, Michigan
Director of Molecular Therapeutics Program, Cancer Drug Discovery Program, and Therapeutics Discovery Program, Univ. of Michigan at Ann Arbor
PI of three inter-connected labs: Computational Chemistry, Medicinal Chemistry, and Pharmacology
Multiple grants from NIH, NCI and other institutes
New drug candidate MI-7701 was licensed to Sanofi with $398M milestone payment
Author of 200+ papers and Over 40 patents
Mr. Dazhong Lv has over 20 years of experience in investment and consulting.
Mr. Lu Dazhong joined SDIC Fund Management Company Ltd. in August 2009 as a managing director and is currently responsible for the company's investment in healthcare. He used to worked for Sino-French Capital, Shanghai NewMargin Ventures Co., Canada Scotiabank, China International Capital Corporation Limited and Arthur Andersen.
Mr. Dazhong Lv holds a Ph.D. from Nankai University and an MBA from McGill University in Canada, and also qualified as a certified public accountant in the United States.
Dr. Lawrence Y. Tian is a Founding Partner of YuanMing Capital. Prior to founding YuanMing Capital, Dr. Tian established China International Futures Corporation and served as Chairman of China Chengtong Group. Dr. Tian has successfully closed a RMB 22 billion restructuring case, and led the efforts to acquire a Hong Kong public company with total asset of HK$2 billion. He operated investment coordination, the sale of assets, and corporate restructuring for the largest ski resort in China, Yabuli Ski Resort, with the total asset upwards of US$ 200 million. He was also responsible for the restructuring and sale of a China famous securities company and its twelve affiliates. Since 2010, Dr. Tian has been committed to promoting China’s capital investment into US life science innovative companies, and has accumulated solid experiences and an outstanding track record.
Dr. Tian is the Founder and Chairman of China Entrepreneurs Forum and Founder and Chairman of China-U.S. Business Leaders Roundtable. He is also a core organizer of various high-end meeting for entrepreneurs of both countries. He is an influential figure in the Sino-China business scene and has extensive social influence.
Dr. Tian obtained his master’s degree and doctoral degree in Wuhan University, he was awarded by the China highest prize for economics: The China Economics Theory Innovation Award.
Partner of Oriza Holdings
Mr. Qun Zhao is the partner of Oriza Holdings. He has held senior management positions in three pharmaceutical companies successively and has fourteen years of experience in the management of pharmaceutical enterprises. His working experience includes traditional Chinese medicine, chemical medicine, vaccines and macromolecular bio-pharmaceuticals. After he stepped into investment area, he completed buyout fund in listed company and worked in Chongyuan Capital.
Mr. Qun Zhao graduated from China Pharmaceutical University with a bachelor's degree and later attended EMBA at Nankai University.
Ms. Ruyan Li was selected as director of Jiangsu Ascentage Pharma Co., Ltd. in December 2015. Ms. Li joined 3S Bio Inc. since 2004 and served successively in the supervisory and legal department of the Company. She is currently the senior legal affairs manager of the legal department of 3S Bio and is responsible for the management of legal affairs.